You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
Y
Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2022-02-23
Feb 23, 2022
C
Active, not recruiting
  • Grade 3b Follicular Lymphoma
  • +15 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Duarte, California
    City of Hope Medical Center
2022-02-17
Feb 17, 2022
B
Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +14 more
  • La Jolla, California
  • +1 more
2022-01-10
Jan 10, 2022
N
Terminated
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
2021-08-30
Aug 30, 2021
D
Recruiting
  • Lymphoma
  • Survivorship
  • Interview with Clinicians
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2022-03-14
Mar 14, 2022
U
Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022
N
Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Chicago, Illinois
  • +2 more
2022-04-05
Apr 5, 2022
J
Recruiting
  • Relapsed Plasmablastic Lymphoma
  • +2 more
  • Belantamab Mafodotin
  • Boston, Massachusetts
  • +2 more
2021-09-20
Sep 20, 2021
N
Not yet recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
2022-01-24
Jan 24, 2022
N
Active, not recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • Pembrolizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
A
Not yet recruiting
  • AIDS-Related Diffuse Large B-cell Lymphoma
  • +14 more
  • Axicabtagene Ciloleucel
  • +2 more
  • (no location specified)
2022-02-15
Feb 15, 2022
W
Terminated
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • New York, New York
    Weill Cornell Medicine
2021-09-20
Sep 20, 2021
J
Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2021-12-17
Dec 17, 2021
M
Active, not recruiting
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
2022-02-03
Feb 3, 2022
M
Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-03
Feb 3, 2022
U
Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • Radiation - Dose Level 0
  • +4 more
  • Chicago, Illinois
    University of Chicago
2021-12-03
Dec 3, 2021
M
Completed
  • Lymphoma
  • 3RP-Lymphoma
  • Boston, Massachusetts
    Massachusetts General Hospital
2021-11-09
Nov 9, 2021
M
Withdrawn
  • Lymphoma
  • Home Hospital for Lymphoma
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
2021-08-31
Aug 31, 2021
S
Completed
  • Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma
    • Seoul, Gangnam-Gu, Korea, Republic of
      Samsung Medical Center
    2022-02-04
    Feb 4, 2022
    U
    Active, not recruiting
    • Non Hodgkin Lymphoma
    • +8 more
    • Miami, Florida
    • +2 more
    2022-03-08
    Mar 8, 2022
    M
    Terminated
    • Central Nervous System Lymphoma
    • +6 more
    • Akt/ERK Inhibitor ONC201
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-03-30
    Mar 30, 2022
    E
    Recruiting
    • Grade 1 Follicular Lymphoma
    • +7 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    2021-12-07
    Dec 7, 2021
    C
    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +19 more
    • CpG-STAT3 siRNA CAS3/SS3
    • Radiation Therapy
    • Duarte, California
      City of Hope Medical Center
    2022-02-28
    Feb 28, 2022
    I
    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
    • Toulouse, France
      Institut Universitaire du Cancer Toulouse - Oncopole
    2022-03-28
    Mar 28, 2022